Welcome to a physician-led video initiative that explores community experience with the long-term use and effect of interleukin-23 (IL-23).
IL-23s: Psoriasis therapy overview
People with moderate-to-severe psoriasis can benefit from tildrakizumab (Ilumya), a biologic treatment that belongs to a class of drugs called interleukin-23 (IL-23) inhibitors. Biologics are protein-based medications that target specific parts of the immune system. IL-23 inhibitor specifically targets a type of cytokine called IL-23 and blocks cellular activity, which results in reduced inflammation that causes psoriasis.
